1. Market Research
  2. > Pharmaceutical
  3. > Drug and Medication Market Trends
  4. > Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure

Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure

  • July 2011
  • -
  • GBI Research

Summary

Table of Contents

Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure

Summary

GBI Research, leading business intelligence provider, has released its latest research report, ‘Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure’, which provides insights into major drug failures during 2005–2010. The 20 drugs included in the report belong to key pharmaceutical companies and were undergoing research for a major indication. The report also includes the total expenditure of top pharmaceutical companies in R&D throughout 1996–2009, and an analysis of the financial loss faced by such companies when a drug fails in the late stages of development.

GBI Research discovered that the economic impact of drug failure during late stage development increased in relation to the escalating cost of development for new therapeutic agents. The main cause of drug failure in Phase III, when the efficacy of the drug is already evaluated, is either its safety measures or its ability to demonstrate any additional benefits in a larger population over a longer time period. Pharmaceutical companies have recently invested substantial amounts of money in R&D processes; in order to combat the threat of patent expires of blockbuster drugs, and to increase the chances of discovering a drug which could generate considerable revenue for the company. If a drug receives approval and is patented, companies’ returns are significantly higher than the amount invested in R&D.

The attrition of molecules occurs at various stages of the trial during drug development process. The majority of molecules fail at the initial stages of development, such as pre-clinical studies and Phase I and II. Pharmaceutical companies face huge losses when drugs fail in the late stage of trials, such as Phase III and the post-marketing stage. According to analysis conducted during 2005–2010, it was found that the number of drugs dropped from the pipeline increased from 2003 to 2007 and furthermore decreased from 2007 to 2010. Many drugs have been discontinued during the course of clinical trials, due to safety and efficacy issues. The decision to discontinue the development of a drug is taken by the health authorities and is based on interim analysis. If the drug is not able to demonstrate any additional benefits over existing therapies, or it has issues related to patient safety, the drug fails to receive approval from health authorities.

Scope

The scope of this report includes -
- Identification of top 20 R&D drug failures
- Unmet need in efficacy and safety for all failed drugs
- Phase II results and the reasons for conducting Phase III
- The reasons for failure and lack of available options for a particular therapeutic area
- Conclusion regarding late-stage drug failures based on the analysis of the top 20 drug failures

Reasons to buy

The report will enhance your decision making capability and will allow you to -
- Build an understanding of recent top R&D late stage drug failures
- Analyze the effect of safety and efficacy parameters on major drug failures
- Identify the unmet needs for a particular indication with the highest drug failures
- Understand the most common reasons for drug failure in late stage of development
- Identify the cost involved in R&D by analyzing the expenditure done by top pharmaceutical companies

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

Get This Report

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

2015 Immunodiagnostics: Spot Fast-Growing Market Segments--Therapeutic Drug Monitoring (TDM), Endocrine Function, Tumor Markers, Special Chemistry, Immunoproteins, Drugs of Abuse

2015 Immunodiagnostics: Spot Fast-Growing Market Segments--Therapeutic Drug Monitoring (TDM), Endocrine Function, Tumor Markers, Special Chemistry, Immunoproteins, Drugs of Abuse

  • $ 15 900
  • Industry report
  • June 2015
  • by Venture Planning Group

Complete report $24,500.  DataPack (test volumes, sales forecasts, supplier shares) $15,900. This comprehensive seven-country report contains 1,115 pages and 450 tables.  The report explores future ...

Antibacterial Drugs Market  - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023

Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023

  • $ 4 795
  • Industry report
  • July 2015
  • by Transparency Market Research

This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs is segmented on the basis of major classes of drugs ...

Future Horizons and Growth Strategies in the European Therapeutic Drug Monitoring (TDM) Market 2015: Supplier Shares and Country Forecasts

Future Horizons and Growth Strategies in the European Therapeutic Drug Monitoring (TDM) Market 2015: Supplier Shares and Country Forecasts

  • $ 4 200
  • Industry report
  • June 2015
  • by Venture Planning Group

This new 291-page report from VPGMarketResearch provides a comprehensive analysis of the European therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.